Syntara (ASX:SNT) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Sep. 26, 2024)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Syntara's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Syntara's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Syntara's Future 3-5Y EPS without NRI Growth Rate falls into.

Syntara (ASX:SNT) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Syntara Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Syntara's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.